Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Cash from Financing Activities of $30.1 million in Q1 2026, down 71.39% quarter-over-quarter from $105.3 million in Q4 2025, and down 73.9% on a YoY basis from $115.5 million in Q1 2025.
Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 73.9% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $134.1 million (down 23.41% YoY), while the FY2025 annual figure was $233.9 million, up 279.56% from the prior year.
- Cash from Financing Activities was $30.1 million for Q1 2026 at Oculis Holding AG, down from $105.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $115.5 million in Q1 2025 to a low of -$2.1 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $30.2 million across 5 years, with a median of $2.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 264.05% in 2024, then surged 58848.04% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$288570.1 in 2022, then surged by 264.08% to $473488.9 in 2023, then surged by 549.73% to $3.1 million in 2024, then surged by 3324.12% to $105.3 million in 2025, then slumped by 71.39% to $30.1 million in 2026.
- The last three Cash from Financing Activities figures came in at $30.1 million (Q1 2026), $105.3 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 30.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.14 Mn |
| Mar 31, 2026 | 30.14 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 730,773.59 |
| Jun 30, 2025 | 730,773.59 |
| Mar 31, 2025 | 115.49 Mn |
| Mar 31, 2025 | 115.49 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | -850,650.74 |
| Sep 30, 2024 | -850,650.74 |
| Jun 30, 2024 | 57.33 Mn |
| Jun 30, 2024 | 57.33 Mn |
| Mar 31, 2024 | 195,911.68 |
| Mar 31, 2024 | 195,911.68 |
| Dec 31, 2023 | 473,488.88 |
| Dec 31, 2023 | 473,488.88 |